Therapeutic | Ravagalimab |
Target | CD40 |
Heavy Chain | EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMNWVRQAPGKGLEWIAYISSGRGNIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSWGYFDVWGQGTTVTVSS |
Light Chain | DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNQKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPLTFGQGTKLEIK |
100% seqID Fv Structure | 6pe7 [Fvs: HL], 6pe8 [Fvs: AB, HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6pe7 [Fvs: HL] |
100% seqID Structure | 6pe8 [Fvs: AB, HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2017 |
INN Year Recommended | 2018 |
Companies Involved | AbbVie |
Conditions Approved | na |
Conditions Active | Ulcerative colitis |
Conditions Discontinued | Crohn's disease |
Notes |